Following intensive discussions, review, alignment of procedures and multiple surveys among their member companies, the European Bioanalysis Forum (EBF) is providing a recommendation on how to integrate incurred sample reproducibility (ISR) in the bioanalytical process. The recommendation aims to provide guidance throughout the lifecycle of a validated method, including the application of the method in study support. In its recommendation, the EBF considers both the internal discussions with EBF member companies, as well as the input provided in international meetings where ISR was discussed. The ultimate goal of the EBF recommendation is to ensure that bioanalytical methods can provide accurate and reproducible concentration data for pharmacokinetic and/or toxicokinetic evaluation, without any compromise, while safeguarding the optimal use of laboratory resources.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4155/bio.09.108 | DOI Listing |
J Pharmacol Toxicol Methods
December 2024
Department of Immunoassay and Immunochemistry, Center for Drug Safety Evaluation and Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; University of Chinese Academy of Sciences, Beijing 101408, China; Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China. Electronic address:
Background: Antibody-drug conjugates (ADCs) are an emerging class of targeted therapeutics and are receiving growing attention in the pharmaceutical field. Here we aimed to validate two ligand binding assays for the quantitation of GQ1001, an ADC made of Trastuzumab site-specifically conjugated with DM1, in cynomolgus monkey serum, and then apply the validated assays to a nonclinical study.
Methods: The quantitative methods for conjugated GQ1001 and total GQ1001 were validated against regulatory guidance documents on bioanalytical method validation under a Good Laboratory Practice (GLP)-compliant environment.
Spectrochim Acta A Mol Biomol Spectrosc
December 2024
Department of Chemistry, Institute of Science, Banaras Hindu University, Varanasi 221005, UP, India. Electronic address:
An efficient molecular probe 8 has been designed and synthesized. The photophysical, electrochemical and morphological behavior of the probe has been examined in the absence and presence of different ions. The probe 8 at 90 % water fraction in acetonitrile showed aggregation induced emission (AIE).
View Article and Find Full Text PDFSmall
December 2024
UMR CNRS 5629, laboratoire LCPO, Université de Bordeaux, Pessac, F-33600, France.
This work addresses the structural quantification of multiphase materials, here nanostructured polymer solid precursors and their micro/nano sized foamed counterparts. It is based on a strategy of contrast/edge enhancement, locally adaptive to image data in digital images of materials. The method allows to binarize straightforwardly the structures (the phases) in TEM and SEM images after edge identification, edge choice, and image virtual reconstruction.
View Article and Find Full Text PDFPLoS One
December 2024
School of Architecture and Civil Engineering, Xi'an University of Science and Technology, Xi'an, China.
Understanding he impact of dry-wet and freeze-thaw cycles on the mechanical properties of unloaded damaged rock masses in reservoir bank slopes is crucial for revealing the deformation and failure mechanisms in artificially excavated slope rock masses within fluctuation zones. To address, the study focuses on unloaded damaged samples subjected to excavation disturbances, conducting various cycles of dry-wet and freeze-thaw treatment along with uniaxial and triaxial re-loading tests. A damage statistical constitutive model was established based on the experimental results and validated using numerical simulation methods.
View Article and Find Full Text PDFAAPS J
December 2024
Bioanalytical Sciences, Genentech, Inc, 1 DNA Way, South San Francisco, California, 94080, USA.
Per FDA guidance, method comparability should be established if an anti-drug antibody (ADA) assay is run by two or more independent laboratories during a study. Genentech, Inc. is evaluating an immunogenicity risk-based comparability approach consisting of both technical and clinical aspects.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!